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Abstract 
Cefovecin is an extended-spectrum long-acting third generation cephalosporin used to 
treat canine infections. The study objective was to determine the effect of cefovecin on the 
absolute number and antimicrobial susceptibility of fecal enteric bacteria in healthy dogs. 
Fourteen Beagles were randomly assigned to a treated (n = 7, 8 mg/kg cefovecin subcutaneously 
on day 1) or untreated (n = 7) group. LC/MS was used to determine plasma cefovecin 
concentration on day 14. E. coli, enterococci, and Salmonella were isolated and enumerated from 
fecal samples collected on days 0, 3, 7, 14, and 28. Antimicrobial resistance was determined 
using disc diffusion, MIC, and detected using PCR for the blaCMY-2 gene on select isolates. 
Mean plasma concentration of cefovecin on day 14 was 9.59 µg/mL in treated dogs; 
untreated dogs had no measurable plasma cefovecin. The absolute number of E. coli was lower 
in treated dogs on day 3 (P ≤ 0.0001), and the absolute number of cefovecin-resistant E. coli was 
higher in treated dogs on days 7 (P = 0.002), 14 (P = 0.004) and 28 (P ≤ 0.0001), compared to 
untreated dogs. Enterococci increased and were higher in the treatment group on day 7 (P = 
0.0226). Isolation of Salmonella was rare. After cefovecin treatment, beta-lactam resistance was 
more common in fecal E. coli from treated dogs than untreated dogs, while resistance of 
enterococci was not altered. On day 28, treated dogs were 3.25 times more likely to carry the 
blaCMY-2 gene than untreated dogs (95% CI 1.27 – 8.35). The implications of these findings in 
clinically ill patients require further research. 
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Chapter 1 - Introduction 
 Literature Review 
Cefovecin is a semi-synthetic third-generation long-acting cephalosporin. It is authorized 
for use in the European Union, New Zealand, and in several countries in South America and 
Asia. In the United States, it is US Food and Drug Administration approved and labeled for the 
treatment of superficial pyodermas, abscesses, and wounds in dogs. In dogs, cefovecin has a 
half-life of 5.5 days, allowing a single subcutaneous (SC) injection to provide up to 14 days of 
treatment (Stegemann et al., 2006a). Cefovecin undergoes minimal hepatic metabolism and is 
primarily excreted unchanged in the urine, but excretion of unchanged drug also occurs in the 
bile resulting in exposure to gastrointestinal (GI) flora (Stegemann et al., 2006a).  
Cephalosporins have a significant effect on the fecal flora of cattle. Calves administered 
intramuscular (IM) ceftiofur hydrochloride had a significantly increased number of ceftriaxone-
resistant fecal bacteria following treatment (Jiang et al., 2006). Cattle administered ceftiofur 
crystalline-free acid had a 2-week increase in multidrug-resistant (ceftiofur, ampicillin, 
chloramphenicol, tetracycline, and sulfisoxazole) Escherichia coli (Lowrance et al., 2007). 
Ceftiofur crystalline-free acid-treated cattle also had increased levels of fecal blaCMY-2 carriage 
(Alali et al., 2009). The blaCMY-2 gene encodes cephalosporin resistance via AmpC β-lactamase 
and has been identified among commensal and pathogenic bacteria within the GI flora of humans 
and animals (Forward et al., 2004; Alali et al., 2009). In vitro conjugation studies have 
documented plasmid transfer of the blaCMY-2 gene within and between fecal genera, specifically 
E. coli and Salmonella spp. (Jiang et al., 2006). Bacteria containing the blaCMY-2 gene produce 
extended spectrum beta lactamases and therefore carry resistance to all beta lactams licensed for 
use in dogs (Damborg et al., 2011). This can pose an animal health problem when selecting an 
antimicrobial to be effective in treating canine infections.  
Few data exist regarding the effect of antimicrobials on canine fecal flora. Oral 
enrofloxacin administered to dogs suppressed fecal coliforms throughout treatment and slowly 
normalized within 8 days after termination of treatment (Trott et al., 2004). A separate study 
evaluating fecal E. coli from dogs found an association between multidrug resistance and history 
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of receiving antimicrobials within 1 month of sampling, suggesting that selection pressure from 
antimicrobial therapy may influence the fecal flora (Stenske et al., 2009). 
 Study Objectives   
The objectives of the present study were (1) to investigate the effect of cefovecin on the 
total number of coliforms and enterococci in the fecal flora of dogs, (2) to investigate the effect 
of cefovecin on the antimicrobial resistance of these bacteria, as determined by disc diffusion, 
minimum inhibitory concentration (MIC) determination, and presence of the antimicrobial 
resistance gene blaCMY-2 on select isolates, and (3) to measure the plasma concentration of 
cefovecin on day 14 to ensure that untreated dogs did not inadvertently receive cefovecin. 
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Chapter 2 - Materials and Methods 
 Study Design and Enrolled Dogs 
The Kansas State University (KSU) Institutional Animal Care and Use Committee 
approved the study (protocol number 2941).  
Fourteen young adult Beagles living in a closed research facility were enrolled. A sample 
size of at least six dogs in each group was calculated based on an estimated 3-log difference in 
bacterial count between treatment groups, with a P value of 0.05, and power of 80 (Trott et al., 
2004). No dogs had received antimicrobials at any time prior to the study, and all dogs were 
deemed healthy based on a physical examination, complete blood count, biochemical profile, and 
fecal flotation examination.  
Dogs were randomly divided, with blocking by age, using a random numbers table into a 
treated group and untreated group. Seven treated dogs received 8 mg/kg cefovecin (Convenia, 
Zoetis) SC on day 1. Seven untreated dogs received no therapy. Dogs were housed in separate 
runs with no direct contact in the month prior to and throughout the study. They ate a dry 
maintenance dog food and received no medication other than the cefovecin (treated dogs) during 
the study. Authors performing bacterial isolation, identification, enumeration, and susceptibility 
testing were blinded to treatment group designation. 
 Bacterial Isolation 
One gram of fresh feces was collected from each of the 14 dogs, via rectal palpation with 
a sterile glove, on days 0, 3, 7, 14, and 28. Feces were diluted 10-fold in 0.1% peptone water and 
spread-plated on EC containing 4-methylumbelliferyl-beta-D-glucuronide agar (EC), Hektoen 
enteric agar (HEA), and mEnterococcus agar (mENT). Additionally, diluted fecal samples were 
spread-plated onto these three media each containing 1 µg/mL cefovecin (EC-CEF, HEA-CEF, 
and mENT-CEF). EC plates were incubated at 44 °C for 24 hours, HEA plates at 37 °C for 24 
hours, and mENT plates at 37 °C for 48 hours.    
 Bacterial Identification 
Isolates on EC plates were considered E. coli if they had the desired morphology, 
fluoresced under 366 nm ultraviolet light, were indole positive, and oxidase negative.  
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Salmonella enrichment was performed by adding 1 mL of the 10
-1
 dilution to 9 mL Rappaport 
broth, incubating for 24 hours at 44 °C, plating on HEA and incubating for an additional 24 
hours. Isolates on HEA were considered Salmonella if they were blue-green colonies that were 
indole negative and oxidase negative. Esculin hydrolysis was used to confirm isolates from 
mENT on the genus level as enterococci. A multiplex PCR assay was performed on three 
random enterococcal isolates grown on mENT plates per fecal sample, to determine the species 
as Enterococcus faecium or Enterococcus faecalis, as previously described (Kariyama et al., 
2000; Poyart et al., 2000). Isolates of E. coli, Salmonella, and enterococci were enumerated as 
colony forming units (CFU) per gram of feces from each fecal sample. Isolates were stored in 
brain heart infusion broth with glycerol at -80 °C. 
 Plasma Cefovecin Concentration Analysis 
Plasma samples were obtained on day 14 from each dog for the determination of 
cefovecin concentration using liquid chromatography (LC) (Shimadzu Prominence, Shimadzu 
Scientific Instruments) with mass spectrometry (MS) (API 2000, Applied Biosystems). Plasma 
standards and samples were processed according to Table 1; the LC settings are described in 
Table 2, and the MS settings in Table 3.  
 Antimicrobial Susceptibility Testing 
To determine the absolute number of cefovecin-resistant fecal bacteria after 
administration of cefovecin, E. coli, Salmonella, and enterococci were enumerated from EC-
CEF, HEA-CEF, and mENT-CEF plates, respectively, at each sampling time. Antimicrobial 
susceptibility testing using the disc diffusion method with Mueller-Hinton agar was performed 
on up to five randomly selected E. coli isolates from each media not containing cefovecin per 
fecal sample on each sampling day. E. coli were tested for susceptibility to 12 antimicrobials, 
enterococci were tested for susceptibility to 10 antimicrobials, and Salmonella were not tested 
for susceptibility.   
Determination of the MIC was performed on five E. coli isolates from each EC plate on 
days 0, 7, and 28 for cefovecin, ceftriaxone, enrofloxacin, gentamicin, and imipenem. Testing 
was performed and interpreted in accordance with the recommendations of the Clinical 
Laboratory Standards Institute (CLSI), using zone diameters and interpretive breakpoints for 
Enterobacteriaceae and Enterococcus spp. for dogs when available, otherwise guidelines for 
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humans were used (CLSI M31-A3 2008; CLSI M100-S20 2010).  The CLSI has not approved 
zone diameters or MIC breakpoint criteria for cefovecin, thus breakpoints used were based on 
recommendations from Zoetis (disc diffusion: S ≥ 24, I 21-23, R ≤ 20 mm; MIC S ≤ 2, I 4, R ≥ 8 
µg/mL). 
Three randomly selected E. coli isolates from EC plates and three randomly selected E.  
coli isolates from EC-CEF plates from each dog on each day were tested using PCR for the 
presence of the blaCMY-2 gene (not necessarily the same isolates as those selected for 
susceptibility testing). E. coli DNA was isolated by boil-prep, and spectrophotometry was used 
to ensure nucleic acid concentration and quality from each E. coli isolate. Real-time PCR was 
performed to determine the presence of the blaCMY-2 gene compared to the eub housekeeping 
gene in the overall fecal population of each dog on each sampling day. Total DNA from 200 µg 
of feces was extracted using QIAamp DNA stool mini kit (Qiagen), following the manufacturer’s 
protocol.   
The blaCMY-2 gene was amplified using forward primer 5
1
GACAGCCTCTTTCTCCACA 
(reference number 59972060), and reverse primer 5
1
GAATAGCCTGCTCCTGCATC (reference 
number 59972061) (Zhao et al, 2001).  PCR amplification (denaturation for 30 seconds at 95 °C, 
primer annealing for 30 seconds at 55 °C, and extension for 30 seconds at 72 °C) consistently 
yields a product size of 101 bp and has been successfully used in DNA from pure cultures or 
total fecal DNA (Zhao et al, 2001). 
 Statistical Method 
Mean age and body weight of enrolled dogs with one standard deviation were calculated, 
and a Student’s t test was used to compared these values between treated and untreated groups. A 
random effects-mixed model was used to analyze bacterial counts in a repeated measures format, 
and data were presented as mean CFU/gram feces ± standard error of the mean. Distribution of 
enterococcal species, antimicrobial resistance testing by disc diffusion, and presence of the 
blaCMY-2 gene in E. coli isolates were analyzed using the Fisher’s exact test and relative risk. 
MIC results were reported as range and MIC90. The presence of the blaCMY-2 gene from the total 
fecal population was achieved by comparing the ratio of the blaCMY-2 gene to the universal 
eubacterial eub gene (bla:eub) in collected fecal samples on each day using a random effects-
mixed model in a repeated measures format. A P-value of <0.05 was considered significant for 
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all analyses. Statistical analyses were evaluated using the commercial software program JMP 9 
(SAS Institute). 
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Chapter 3 - Results 
 Enrolled Dogs 
Six male intact and eight female intact Beagles were enrolled.  Mean age was 11.57±0.94 
months and body weight was 9.69±1.26 kg; there was no difference in age (P = 0.589) or body 
weight (P = 0.921) between groups.  No adverse clinical signs were noted in any dog. 
 Plasma Cefovecin Concentration 
The average plasma cefovecin concentration on day 14 in treated dogs was 9.59 µg/mL 
(range 3.20-12.90 µg/mL). Cefovecin was not detected in any untreated dogs. 
 Fecal Bacterial Counts 
On day 0, a mean of 6.7±1.8 x 10
6
 CFU of E. coli per gram of feces was isolated, with no 
difference identified between treated and untreated dogs (Figure 1). Thereafter, a significant time 
* treatment group interaction was identified (P < 0.0001), and on day 3 the absolute number of 
fecal E. coli dropped significantly in the treated group (Figure 1). Based on the absolute number 
of E. coli grown on media containing cefovecin, resistance to cefovecin among E. coli increased 
throughout the study and was significantly greater in the treated vs. untreated dogs on days 7, 14, 
and 28 (Figure 2).  
Salmonella isolation was rare, even with enrichment. Salmonella spp. were isolated from 
the feces of six dogs (3 treated, 3 untreated), but no effect of treatment (P = 1.000) or interaction 
between treatment and time (P = 0.676) was identified. Cefovecin-resistant Salmonella were 
isolated from one treated and one untreated dog on day 28 but not on other days.   
On day 0, a mean of 1.3±0.7 x 10
7 
CFU of enterococci per gram of feces was found, with 
no difference between treated and untreated dogs (P = 1.000).  However, a significant time * 
treatment group interaction was identified (P = 0.002), with more enterococci isolated from feces 
of treated dogs compared with untreated dogs on day 7 (P = 0.023). No differences were seen in 
enumeration of cefovecin-resistant enterococci between groups at any time point.  All 
enterococcal isolates were identified with PCR as either E. faecalis or E. faecium. E. faecalis 
were more common than E. faecium in both groups on day 0, but the percentages of E. faecalis 
isolates decreased and E. faecium isolates increased until day 14 (Figure 3). By day 3 isolates 
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from treated dogs (12/21, 66.7%) were 14 times as likely as from untreated dogs (1/21, 4.8%) to 
be E. faecium (P < 0.0001, 95% CI 2.0-97.5), but by day 7 there was no difference in species 
distribution between groups (P = 0.520), with feces from both treated and untreated dogs having 
E. faecium percentage peaking at 14 days. 
 Antimicrobial Resistance 
Based on disc diffusion testing, there were no differences in susceptibility between E. 
coli (EC plates) from treated and untreated dogs on day 0, but resistance to cefovecin was high in 
both groups (Figure 4). On days 3, 7, 14, and 28, significant differences were observed, with 
fecal E. coli from treated dogs being more likely to be resistant to numerous tested antimicrobials 
than feces from untreated dogs (Figures 5-8).  
Based on disc diffusion testing, from the population of E. coli that grew on media 
containing cefovecin (EC-CEF), all isolates from all treated and untreated dogs on all sampling 
days were resistant to cefovecin, as well as to ampicillin, cefazolin, and cefpodoxime. Of tested 
isolates from treated and untreated dogs, >97% were resistant to amoxicillin-clavulanic acid at 
each sampling time, and >33% were resistant to ceftiofur. In these isolates, ceftriaxone resistance 
increased in both groups from day 0 (20% treated, 28% untreated) to day 28 (82.9% treated, 
77.1% untreated), with no group effect. All E. coli isolates from EC-CEF were susceptible (via 
disc diffusion) to gentamicin and imipenem, while resistance to doxycycline, enrofloxacin, and 
TMS increased throughout the study, with no group effect.   
MIC was performed on E. coli isolated from EC plates from treated and untreated dogs 
on days 0, 7, and 28 for cefovecin, ceftriaxone, enrofloxacin, gentamicin, and imipenem, and 
compared based on previous categorization (via disc diffusion) of E. coli as being cefovecin-
susceptible or cefovecin-resistant (Table 4).   
At baseline, presence of the blaCMY-2 gene was isolated from the fecal E. coli of 14.3% 
(3/21) of treated and 4.8% (1/21) of untreated dogs (P = 0.606). No treatment group differences 
were noted until day 28 when fecal E. coli (from EC plates) from treated dogs (62%, 13/21) were 
3.25 times more likely (95% CI 1.27-8.35) than fecal E. coli from untreated dogs (19%, 4/21) to 
carry the blaCMY-2  gene (P = 0.010). While the percent of fecal E. coli containing the blaCMY-2 
gene increased over the study period (14-76%) among those isolates tested from EC-CEF plates, 
no significant treatment group differences were documented. The ratio of the blaCMY-2 gene to 
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the universal eubacterial gene, bla:eub, was then assessed in the total fecal bacterial population 
of enrolled dogs. Contrary to what was found when assessing presence of blaCMY-2  in E. coli 
alone, the feces of untreated dogs had a higher mean bla:eub (2.714±0.84) compared with the 
feces of treated dogs (1.667±0.28) on day 28 (P < 0.0001); no differences were found on other 
days, and there was no significant change over time (P = 0.145). 
Treatment group had no effect on antibiotic susceptibility within E. faecalis or E. faecium 
isolates over the study time period, with the exception of day 28 E. faecium isolates from treated 
dogs (94.4%) which were more frequently resistant to tigecycline than isolates from untreated 
dogs (54.6%) (P = 0.019).  Percent resistance to each antimicrobial of all E. faecalis and E. 
faecium isolates together are presented in Figure 9.
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Chapter 4 - Discussion 
Plasma cefovecin concentrations confirmed that no untreated dog inadvertently received 
cefovecin. Cefovecin concentrations in treated dogs on day 14 (3.20–12.90 µg/mL) were similar 
to a previous study which reported 5.6 ± 1.8 µg/mL and 15.2 ± 3.2 µg/mL in two groups of dogs 
14 days after administration (Stegemann et al., 2006a). A second study reported the in vitro 
MIC90 of cefovecin for E. coli isolates from the United States was 1 µg/mL; however the 
correlation between in vitro MIC90 and in vivo plasma concentration, especially for highly 
protein bound drugs such as cefovecin, has not been determined (Stegemann et al., 2006b).  
Due to the bacterial isolation and identification techniques used, only typical Salmonella, 
E. coli, and enterococci were selected for analysis. Any atypical isolates that might have been 
present were not analyzed.  
The significant decline in total number of E. coli within 72 hours of cefovecin 
administration was similar to that seen with oral enrofloxacin administration to dogs (Trott et al., 
2004). However, in that study, total coliform numbers remained below detectable limits 
throughout antimicrobial administration (21 days) followed by a return to untreated levels within 
8 days after ceasing administration, while in the current study total E. coli levels returned to 
levels consistent with untreated dogs by day 7 despite treated dogs having measurable cefovecin 
in their plasma on day 14 (Trott et al., 2004). One potential explanation would be differences in 
gastrointestinal exposure of cefovecin and enrofloxacin.  
The absolute number of cefovecin-resistant E. coli increased over the study period in 
untreated dogs as well as treated dogs. The authors hypothesized that this was caused by fecal 
oral cross-contamination which may have occurred between the two groups of dogs despite 
deliberate efforts to prevent this, including prohibiting direct contact among dogs, housing in 
runs with solid walls to prevent fecal spread between kennels, and keeping kennels clean. 
Suspected cross-contamination is a limitation of the present study, and more aggressive attempts 
to prevent any contact between the dogs or their feces should be made for future research studies 
(i.e. separate wards, foot baths, etc.). However, the effects of suspected cross-contamination may 
be relevant to a clinical hospital setting, where dogs are in kennels next to each other and similar 
precautions (no direct contact, keeping kennels clean, wearing gloves) are taken to minimize 
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disease transmission. Thus, it is reasonable to believe that resistant bacteria could be shed from a 
patient receiving antimicrobials and transferred to a dog in a nearby kennel, which could be 
deleterious if the recipient is highly susceptible to infection, such as an immunosuppressed 
patient. A public health risk could also be inferred, as resistant fecal bacteria could be spread to 
the veterinary staff or dog’s owner.  
Disc diffusion and MIC testing of E. coli from EC plates identified a high percentage of 
cefovecin-resistant E. coli at baseline and throughout the study in treated and untreated dogs. The 
most reliable measure of cefovecin resistance in this study was from enumeration of absolute 
numbers of cefovecin-resistant E. coli grown on EC–CEF media at each sampling day, and this 
technique found a lower rate of cefovecin-resistance at baseline in both groups. One explanation 
for this discrepancy could be that without CLSI approved zone diameters and breakpoint criteria, 
the manufacturer-recommended breakpoint criteria may need to be re-evaluated. It was also 
possible that the enrolled dogs may have had cefovecin resistance prior to the study from 
maternal or environmental exposure to resistant bacteria.  
Significant differences occurred between treated and untreated dogs in the percentage of 
resistant E. coli isolates via disc diffusion to other beta-lactams after administration of cefovecin. 
The difference in blaCMY-2 carriage identified on day 28 from fecal E. coli of treated and 
untreated dogs may indicate that cefovecin treatment selects for E. coli producing a plasmid-
borne CMY-2 beta-lactamase. A study of dogs with pyoderma also found that treatment with 
cephalexin resulted in fecal E. coli from 8/13 dogs carrying plasmid-mediated blaCMY-2 
(Damborg et al., 2011). Acquisition of this gene may explain the cross resistance seen among β-
lactams in this study. Furthermore, co-residence of multiple resistance genes has been 
documented in E. coli carrying the blaCMY-2 gene, which may help to explain the resistance seen 
in the fecal E. coli of the present study to doxycycline, enrofloxacin, gentamicin, and imipenem 
(Winokur et al., 2001).  
The significant increase in the number of enterococci isolated from treated dogs 
compared with untreated dogs on day 7 was not surprising, as enterococci are not susceptible to 
cefovecin and would have a competitive advantage when other enteric flora (E. coli) are 
eliminated by cefovecin. At day 0 of this study, E. faecalis was the predominant enterococcal 
species (88%), which is consistent with a previous report of canine rectal swabs (n = 86) that had 
a species distribution of E. faecalis (60%), E. hirae (15%), and E. faecium (8%) (Jackson et al., 
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2009). It is possible that cefovecin contributed to the change in species distribution towards a 
higher percentage of E. faecium, but no mechanism for this effect is known; sampling bias from 
random selection of colonies may have also played a role in this change. 
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Chapter 5 - Conclusion 
This study documented that cefovecin administration impacted both the number and 
antimicrobial resistance of fecal E. coli in healthy dogs. However, the clinical implications of the 
results are unknown as the work was performed using young healthy dogs in a research setting. 
Future studies are recommended to assess the effect of other cephalosporins, route of 
administration, and other classes of antimicrobials on the canine gastrointestinal flora, as well as 
the effect of these drugs on the flora of clinically ill patients. The results from this study suggest 
that antimicrobials should only be prescribed to dogs when benefits to the patient clearly out-
weigh the risks. 
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Figures and Tables  
Figure 1. Absolute number of fecal E. coli presented as log CFU/g feces from treated and 
untreated dogs. Error bars represent standard error. *P ≤ 0.0001 
 
Figure 2. Absolute number of fecal cefovecin-resistant E. coli isolated from EC-CEF plates 
presented as log CFU/g feces from treated and untreated dogs. Error bars represent 
standard error.  *P = 0.002, ^P = 0.004, 
#
P < 0.001. 
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Figure 3. Percent of each enterococcal species by PCR on each sampling day from both 
groups combined. 
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Figure 4. Percent of fecal E. coli that were resistant to tested antimicrobials via the disc 
diffusion method on day 0. No differences were documented between treated and untreated 
dogs. 
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Figure 5. Percent of fecal E. coli that were resistant to tested antimicrobials via the disc 
diffusion method on day 3. *Signifies P < 0.05. 
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Figure 6. Percent of fecal E. coli that were resistant to tested antimicrobials via the disc 
diffusion method on day 7. *Signifies P < 0.05. 
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Figure 7. Percent of fecal E. coli that were resistant to tested antimicrobials via the disc 
diffusion method on day 14. *Signifies P < 0.05. 
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Figure 8. Percent of fecal E. coli that were resistant to tested antimicrobials via the disc 
diffusion method on day 28. *Signifies P < 0.05. 
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Figure 9. Percent of fecal E. faecalis and E. faecium resistant to each antimicrobial, based 
on disc diffusion testing. q/d, quinupristin-dalfopristin. There was no significant difference 
between the treatment groups for each antimicrobial. 
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Table 1. Sample preparation for the determination of cefovecin concentration in plasma 
and plasma standards. 
Step  
1 Add 0.1 mL plasma or plasma standard to microcentrifuge tube 
2 Add 0.4 mL methanol containing cephalexin 0.5 µg/mL to 
microcentrifuge tube 
3 Vortex microcentrifuge tube for 5 s 
4 Centrifuge microcentrifuge tube at 15,000 g for 5 min 
5 Transfer 0.2 mL supernatant to injection vial 
 
Table 2. Mobile phase for the determination of cefovecin in plasma and plasma standards. 
A C18 column (Supelco Discovery, 50 x 2.1 mm, 5µM, Sigma) achieved separation while 
maintained at 40 °C. 
 Mobile Phase 
Time (min) A = Acetonitrile B = 0.1% formic acid in water 
0 5% 95% 
1 20% 80% 
3.5 5% 95% 
5.5 5% 95% 
 
Table 3. Mass spectrometry settings for the determination of cefovecin concentration in 
plasma using cephalexin as the internal standard. The accuracy and coefficient of variation 
were determined on replicates of three at each of the following concentrations: 0.05, 1, and 
50 µg/mL. 
 Qualifying ion 
(m/z) 
Quantifying ion 
(m/z) 
Accuracy Coefficient of 
variation 
Linear standard 
curve range 
Cefovecin 454.08 241.00 99.6% 3.8% 0.05-50 µg/mL 
Cephalexin 348.09 158.00 N/A N/A N/A 
N/A not applicable 
 
Table 4. MIC range and MIC90 values for tested antimicrobials among cefovecin-
susceptible and cefovecin-resistant E. coli collected on days 0, 7, and 28. 
 Day 0 
Cef-S 
N=26 
Day 0 
Cef-R 
N=44 
Day 7 
Cef-S 
N=6 
Day 7 
Cef-R 
N=64 
Day 28 
Cef-S 
N=4 
Day 28 
Cef-R 
N=66 
Cefovecin 
 
Range 
<0.625-
Range 
<0.625-
Range 
 1.25-
Range 
1.25->200 
Range  
60->200 
Range  
20->200 
25 
 
10 
MIC90 10 
200 
MIC90 60 
>200 
MIC90 
N/A 
MIC90 
>200 
MIC90 
N/A 
MIC90 
>200 
Ceftriaxone Range 
<0.625-5 
MIC90 5 
Range 
<0.625-5 
MIC90 5 
Range  
1.25-2.5 
MIC90 
N/A 
Range 
0.25->200 
MIC90 
>200 
Range  
1.25-10 
MIC90 
N/A 
Range  
1.25-20 
MIC90 20 
Enrofloxacin Range  
0.5-16 
MIC90 2 
Range  
0.5-16 
MIC90 16 
Range  
2-16 
MIC90 
N/A 
Range  
0.5->200 
MIC90 
>200 
Range  
0.5-2 
MIC90 
N/A 
Range  
<0.5-100 
MIC90 16 
Gentamicin Range 
5-20  
MIC90 
20 
Range  
5-20 
MIC90 20 
Range 
10-20 
MIC90 
N/A 
Range 
 10->200 
MIC90 
>200 
Range 
5-10 
MIC90 
N/A 
Range 
2.5-20 
MIC90 10 
Imipenem Range 
<0.625-
20 
MIC90 5 
Range 
<0.625-5 
MIC90 5 
Range 
1.25-20 
MIC90 
N/A 
Range  
1.25->200 
MIC90 
>200 
Range 
<0.625-
1.25 
MIC90 
N/A 
Range 
0.625-20 
MIC90 10 
Cef-S, cefovecin-susceptible based on disc diffusion; Cef-R, cefovecin-resistant based on disc 
diffusion; N/A, not applicable 
 
 
 
 
 
